Cornerstone Pharmaceutical-B (02616) is included in the Hang Seng Composite Index and is expected to become the Hong Kong Stock Exchange Standard

Zhitong Finance App learned that on August 21, 2026, Hang Seng Index Company announced the results of the Hang Seng Index series of quarterly reviews up to June 30, 2026. Among them, Cornerstone Pharmaceutical-B (02616) was included in the Hang Seng Composite Index. Changes in the Hang Seng Composite Index will be implemented after the market closes on September 4 (Friday) and will take effect on September 7 (Monday). At that time, the Shanghai and Shenzhen Stock Exchange will adjust the scope of investment targets of Hong Kong Stock Connect accordingly. Cornerstone Pharmaceutical-B (02616) is likely to be transferred to the Hong Kong Stock Connect because it meets a range of criteria including market value and liquidity.

Cornerstone Pharmaceutical-B (02616) announced that the new drug clinical trial application (IND) of CS5007 (EGFR/HER3 bispecific antibody conjugate drug [ADC]), one of the core drug candidates in the company's pipeline 2.0, was quickly approved through the China National Drug Administration (NMPA) innovative drug clinical trial review and approval channel. The whole process took only 23 working days. This achievement not only reflects the company's clinical and registration team's policy insight, proactive communication ability and forward-looking strategic layout under the new regulatory framework, but also marks that the molecule's early development data and clinical development plan have been confirmed by the regulatory authorities in stages, laying a solid foundation for the promotion of subsequent clinical trials. Previously, the global multi-center phase I clinical trial of CS5007 was initiated in Australia in June 2026 and the first patient enrollment was completed. The trial will also be carried out simultaneously in China.